Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan
· Delayed Price · Currency is TWD 47.30
+0.30 (0.64%)
Apr 24, 2025, 1:20 PM CST
Pharmosa Biopharm Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Cash & Equivalents | 749.44 | 974.06 | 672.51 | 461.46 | 414.54 | Upgrade
|
| Short-Term Investments | 869 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 1,618 | 974.06 | 672.51 | 461.46 | 414.54 | Upgrade
|
| Cash Growth | 66.16% | 44.84% | 45.73% | 11.32% | 9672.18% | Upgrade
|
| Accounts Receivable | 4.65 | - | - | - | - | Upgrade
|
| Other Receivables | 6.69 | 1.47 | 0.29 | 0.31 | 0.15 | Upgrade
|
| Receivables | 11.34 | 1.47 | 0.29 | 0.31 | 0.15 | Upgrade
|
| Inventory | 24.74 | 21.91 | - | - | - | Upgrade
|
| Prepaid Expenses | 27.22 | 12.67 | 11.65 | 14.18 | 8.69 | Upgrade
|
| Other Current Assets | - | - | - | 0.02 | 4 | Upgrade
|
| Total Current Assets | 1,682 | 1,010 | 684.45 | 475.96 | 427.37 | Upgrade
|
| Property, Plant & Equipment | 315.06 | 180.61 | 30.12 | 33.44 | 40.86 | Upgrade
|
| Long-Term Investments | 73.26 | 71.22 | 65.69 | 61.6 | 60.91 | Upgrade
|
| Other Intangible Assets | 0.66 | 0.09 | 0.15 | 0.18 | - | Upgrade
|
| Other Long-Term Assets | 92.88 | 71.62 | 18.95 | 15.19 | 14.13 | Upgrade
|
| Total Assets | 2,164 | 1,334 | 799.37 | 586.37 | 543.27 | Upgrade
|
| Accounts Payable | 0.68 | 0.59 | - | - | - | Upgrade
|
| Accrued Expenses | 61.51 | 33.24 | 12.28 | 11.66 | 10.43 | Upgrade
|
| Short-Term Debt | - | - | - | - | 61 | Upgrade
|
| Current Portion of Long-Term Debt | - | 1.26 | 3.52 | 8.43 | 18.81 | Upgrade
|
| Current Portion of Leases | 17.98 | 24.69 | 7.19 | 6.8 | 6.43 | Upgrade
|
| Current Unearned Revenue | 6.89 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 29.07 | 17.8 | 4.77 | 6.19 | 2.58 | Upgrade
|
| Total Current Liabilities | 116.13 | 77.58 | 27.77 | 33.07 | 99.25 | Upgrade
|
| Long-Term Debt | - | 1.19 | 2.45 | 5.96 | 14.83 | Upgrade
|
| Long-Term Leases | 99.62 | 117.23 | 8.04 | 15.9 | 23.36 | Upgrade
|
| Long-Term Unearned Revenue | 4.82 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 5.1 | - | - | - | - | Upgrade
|
| Total Liabilities | 225.66 | 195.99 | 38.25 | 54.93 | 137.44 | Upgrade
|
| Common Stock | 645.43 | 586.02 | 554.67 | 489.24 | 402.5 | Upgrade
|
| Additional Paid-In Capital | 1,439 | 531.34 | 1,180 | - | 454.19 | Upgrade
|
| Retained Earnings | -146.37 | 20.28 | -973.44 | -706.94 | -450.46 | Upgrade
|
| Comprehensive Income & Other | 0.02 | 0.01 | 0.01 | 749.13 | -0.41 | Upgrade
|
| Shareholders' Equity | 1,938 | 1,138 | 761.12 | 531.44 | 405.83 | Upgrade
|
| Total Liabilities & Equity | 2,164 | 1,334 | 799.37 | 586.37 | 543.27 | Upgrade
|
| Total Debt | 117.6 | 144.37 | 21.19 | 37.09 | 124.43 | Upgrade
|
| Net Cash (Debt) | 1,501 | 829.69 | 651.32 | 424.37 | 290.1 | Upgrade
|
| Net Cash Growth | 80.89% | 27.39% | 53.48% | 46.28% | - | Upgrade
|
| Net Cash Per Share | 11.87 | 7.32 | 6.61 | 5.00 | 6.09 | Upgrade
|
| Filing Date Shares Outstanding | 129.09 | 117.2 | 110.93 | 97.85 | 49.99 | Upgrade
|
| Total Common Shares Outstanding | 129.09 | 117.2 | 110.93 | 97.85 | 49.99 | Upgrade
|
| Working Capital | 1,566 | 932.53 | 656.68 | 442.89 | 328.12 | Upgrade
|
| Book Value Per Share | 15.01 | 9.71 | 6.86 | 5.43 | 8.12 | Upgrade
|
| Tangible Book Value | 1,937 | 1,138 | 760.97 | 531.25 | 405.83 | Upgrade
|
| Tangible Book Value Per Share | 15.01 | 9.71 | 6.86 | 5.43 | 8.12 | Upgrade
|
| Machinery | 68.34 | 27.11 | 26.37 | 17.05 | 19.59 | Upgrade
|
| Construction In Progress | 134.42 | - | - | - | - | Upgrade
|
| Leasehold Improvements | 28.85 | 35.61 | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.